Plenary

01 FAECAL VOLATILE ORGANIC COMPOUNDS IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE

^{1,2}Salma Belnour, ²Rachael Slater, ³Marcus KH Auth, ⁴Rafeeq Muhammed, ⁵Christine Spray, ²Duolao Wang, ¹Chris Probert, ²Stephen Allen. ¹University of Liverpool; ²Liverpool School of Tropical Medicine; ³Alder Hey Children's Hospital NHS Foundation Trust; ⁴Birmingham Children's Hospital NHS Foundation Trust; ⁵Bristol Royal Hospital for Children

10.1136/flgastro-2021-bspghan.1

Faecal volatile organic compounds (VOCs) result from the metabolism of the intestinal mucosa, gut microbiota and the environment. Profiling of faecal VOCs in children with different IBD sub-types and disease distribution and activity may shed light on underlying disease mechanisms.

Method We assessed faecal VOCs by gas chromatography-mass spectrometry in a prospective, observational study of children with suspected inflammatory bowel disease (IBD) attending 3 specialist clinics. We tested whether the abundance of faecal VOCs differed according to IBD versus other gastrointestinal disorders, IBD subtype and response to treatment in IBD.

Results We characterised faecal VOCs in 132 children in whom IBD was diagnosed and 132 non-IBD controls. 162 (61.4%) were boys. Mean age was 12.2 years (SD 3.0). In total 214 (81.1%) were white, 35 (13.3%) were Asian and 15 (5.7%) of other ethnic background. There were 78 (29.5%) children with Crohn's disease (CD), 38 (14.4%) with ulcerative colitis (UC) and 16 (6.1%) IBD-unclassified. The most common diagnosis in controls was a functional gastrointestinal disorder.

The mean abundance of 16 VOCs was significantly lower in IBD than controls whereas phenol and propan-1-ol were higher in IBD ($p=0.001$). Some short chain fatty acids (butanoic, pentanoic and hexanoic acids) were lower in IBD than controls ($p<0.03$).

The two compounds that were more abundant in IBD than control (propan-1-ol and phenol) returned to control levels post-treatment (figure 1).

Within IBD, the subtype (CD versus colitis (UC and IBD-unclassified)) described a small amount of variation (3%, $p=0.006$), with three faecal VOCs (6-methylhept-5-en-2-one;

benzaldehyde; 4-methylphenol) significantly different in abundance between CD and colitis (t-test, $p<0.05$).

Conclusion/interpretation Propan-1-ol and phenol, higher in abundance in IBD than controls and returning to control levels post-treatment, may indicate abnormal amino-acid metabolism in pre-treatment IBD; phenol may be pro-inflammatory. Further analysis of VOCs may provide insights into underlying disease mechanisms in paediatric IBD.

02 LONG-TERM OUTCOMES OF PAEDIATRIC LIVER TRANSPLANTATION USING ORGAN DONATION AFTER CIRCULATORY DEATH (DCD); COMPARISON BETWEEN FULL AND REDUCED GRAFTS

^{1,2}Amr Alnagar, ¹Kejd Bici, ³Thamara Perera, ³Darius Mirza, ³Paolo Muesan, ¹E Ong, ¹Girish Gupta, ¹Indra Van Mourik, ¹Jane Hartley, ¹Deirdre Kelly, ¹Khalid Sharif. ¹Birmingham Women's and Children's NHS Foundation Trust; ²General Surgery Department, Faculty of Medicine, Alexandria University, Egypt; ³University Hospitals Birmingham NHS Foundation Trust

10.1136/flgastro-2021-bspghan.2

Background Increasing numbers of successful paediatric liver transplantation (PLT) with improved survival rates reaching 90% at 10 years resulted in more children being listed for PLT but this was not associated with matching expansion in graft pool resulting in graft shortage. Reports including our published early experience showed promising short and intermediate term outcomes from DCD grafts in children.

Aim To compare long-term outcomes of full size and reduced DCD grafts in terms of incidence of complications as well as survival of both recipients and grafts.

Methods This is a retrospective review of PLTs using DCD grafts. Patients were divided into those who received full or reduced grafts. Data was collected for comparison of pre-transplant recipient parameters, donor parameters, operative parameters, post-transplant recipient parameters and outcomes. Laboratory markers were checked at discharge, 1- and 5-years post-transplant.

Results 14 PLTs from DCD donors between 2005 and 2018 were identified; 9 full size and 5 reduced grafts. Donors of both groups were Maastricht category III donors. Functional warm ischemia time did not show significant difference while

Abstract 01 Figure 1 Box and whisker plots of propan-1-ol and phenol

Abstracts

cold ischemia time was significantly longer in reduced graft group. Recipients of full grafts were significantly older, heavier in weight and tend to wait significantly longer on transplant

Abstract O2 Table 1

Parameter	Full DCD graft (n = 9)	Reduced DCD graft (n = 5)	P
Recipient age at transplant (months)			
Mean $\pm$ SD.	143.4 $\pm$ 66.1	40.5 $\pm$ 53.8	0.012*
Median (Min. – Max.)	180 (11 – 216)	7 (0.8 – 120)	
Recipient weight at transplant(kg)			
Mean $\pm$ SD.	41.6 $\pm$ 19.9	11.2 $\pm$ 10.9	0.012*
Median (Min. – Max.)	43 (10 – 73)	5.3 (3 – 28.4)	
Waiting time (days)			
Mean $\pm$ SD.	170.8 $\pm$ 142.8	21.2 $\pm$ 18.8	0.012*
Median (Min. – Max.)	168 (4 – 487.)	22 (1 – 49)	
Pre-transplant recipient condition:			
1-Admitted electively from home.	6	0	
2- Hospitalized for intractable variceal bleeding.	1	0	
3- Hospitalized for worsened liver function or nutritional rehabilitation.	2	0	
4-Recurrent episodes of cholangitis $\pm$ external biliary drainage.	0	2	
5-Super urgently listed for acute liver failure $\pm$ ventilatory and renal support.	0	3	
Cold ischemia time (Hours):			
Median (Min. – Max.)	6.2 (4.2– 9)	8.2 (7 – 8.8)	P=0.038*
Biliary complications			
- stricture	2 (22.2%)	1 (20%)	
- stricture + leak	1 (11.1%)	0 (0%)	
Laboratory markers at 1 year:			
-ALT			
Mean $\pm$ SD.	20.6 $\pm$ 13.3	123.8 $\pm$ 102.6	0.016*
Median (Min. – Max.)	15 (14 – 53)	113.5 (31 – 237)	
- AST			
Mean $\pm$ SD.	29.6 $\pm$ 11.6	81.7 $\pm$ 62.7	0.497
Median (Min. – Max.)	26 (17 – 51)	96 (13 – 136)	
- Bilirubin			
Mean $\pm$ SD.	33.5 $\pm$ 31.3	19.3 $\pm$ 13.8	0.921
Median (Min. – Max.)	16 (6 – 71)	14 (9 – 35)	
-Albumen			
Mean $\pm$ SD.	45.3 $\pm$ 2.1	40 $\pm$ 6.2	0.047*
Median (Min. – Max.)	45 (41 – 48)	40.5 (32 – 47)	
- Urea			
Mean $\pm$ SD.	5.3 $\pm$ 1.1	4.1 $\pm$ 1.0	0.081
Median (Min. – Max.)	5.6 (3.8 – 6.7)	4.1 (3.2 – 5)	
- Creatinine			
Mean $\pm$ SD.	52.6 $\pm$ 11.8	28.3 $\pm$ 13.4	0.016*
Median (Min. – Max.)	51 (31 – 73)	26 (16 – 45)	
Vascular complications			
-PVS	1 (11.1%)	1 (20%)	
-PVT	0 (0%)	1 (20%)	
Rejection			
	3(33.3%)	2/5 (40%)	
Re-operation:			
-Re-transplantation	0 (0%)	1 (20%)	
-Biliary re-construction	2 (22.2%)	0 (0%)

Abstract O2 Figure 1 Kaplan-Meier patient survival curve

Abstract O2 Figure 2 Kaplan-Meier graft survival curve

waiting list. The main indications for PLT were biliary atresia and Alpha-1 anti-trypsin deficiency. Recipients of reduced grafts were sicker pre-transplant. Post-transplant hospital and PICU stay were longer in the reduced group but this was not significant. Only significant laboratory difference was at 1-year post-transplant as albumen and creatinine were significantly higher in the full graft group while ALT was significantly higher in the reduced graft group. There was no significant difference between two groups in terms of long-term complications. 3 patients in each group survived more than 5 years post-transplant. one child was re-transplanted in the reduced group due to portal vein thrombosis, this patient received another DBD graft then unfortunately died due to liver failure. One child from full graft group also died from a non-graft related cause (figures 1, 2).

Summary 14 PLTs from DCD grafts (9 full and 5 reduced) were identified. Recipients of full grafts were older and heavier while reduced graft recipients were sicker in the pre-transplant period. Both groups demonstrated comparable graft and patient survival as well as long-term complications rates.

Conclusion Selected DCD grafts are potential source to widen the graft pool in children